NCT00005652View on ClinicalTrials.gov

Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2000

Primary Completion Date

August 31, 2007

Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
DRUG

rituximab

Trial Locations (1)

35294

University of Alabama Comprehensive Cancer Center, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT00005652 - Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura | Biotech Hunter | Biotech Hunter